Filtered By:
Source: The American Journal of Cardiology
This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 715 results found since Jan 2013.
Effect of Mitral Regurgitation on Thrombotic Risk in Patients with Nonrheumatic Atrial Fibrillation: a New CHA2DS2-VASc Score Risk Modifier?
Atrial fibrillation (AF) significantly increases the risk of ischemic stroke (IS), but the risk varies strongly depending on the individual patient's stroke risk factors.1 Many scores, such as the CHA2DS2-VASc score, have been developed to guide physicians in their decision to start anticoagulation.2 However, the risk prediction with these models is modest at best (C-statistic = 0.6).3,4 Severe mitral regurgitation (MR) has been shown to decrease left atrial (LA) thrombus formation and systemic thromboembolic (TE) events in AF patients with rheumatic valve disease with an observed risk reduction of more than 50%.
Source: The American Journal of Cardiology - January 14, 2021 Category: Cardiology Authors: Sven L. Van Laer, Seppe Verreyen, Koen M. Winkler, Hielko Miljoen, Andrea Sarkozy, Hilde Heuten, Johan Saenen, Paul Van Herck, Caroline M. Van de Heyning, Hein Heidbuchel, Marc J. Claeys Source Type: research
Direct Oral Anticoagulants in Cardiac Amyloidosis –Associated Heart Failure and Atrial Fibrillation
Atrial fibrillation (AF) is present in approximately 40% of patients with cardiac amyloidosis.1 AF in the setting of cardiac amyloidosis is associated with a significant risk of stroke and systemic thromboembolism regardless of the patient's CHA ₂DS₂-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category) score.2 Although current guidelines recommend anticoagulation therapy in all patients with cardiac amyloidosis and AF, data about the comparative effectiveness and safety of vitamin K antagonists (VKAs) ...
Source: The American Journal of Cardiology - November 27, 2021 Category: Cardiology Authors: Amgad Mentias, Paulino Alvarez, Pulkit Chaudhury, Michael Nakhla, Rohit Moudgil, Mohamad Kanj, Mazen Hanna, Milind Y. Desai Source Type: research
Relation of Cannabis Use to Elevated Atherosclerotic Cardiovascular Disease Risk Score
We hypothesized that cannabis use is associated with cardiovascular disease (CVD) risk factors. This could explain the reported link between cannabis and cardiovascular events including stroke and myocardial infarction. This analysis included 7,159 participants (age 37.8 ± 12.4 years, 48.6% men, and 61.5% Caucasian) from the National Health and Nutrition Examination Survey years 2011 to 2018. Cannabis use was defined by self-report. Participants with a history of stroke or myocardial infarction were excluded.
Source: The American Journal of Cardiology - December 17, 2021 Category: Cardiology Authors: Travis M. Skipina, Nikhil Patel, Bharathi Upadhya, Elsayed Z. Soliman Source Type: research
Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation
To compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by real-world evidence. Systematic review and meta-analysis of observational studies including patients with NVAF on apixaban and rivaroxaban, which reported stroke/systemic embolism and/or major bleeding. Prospero registration number: CRD42021251719. Estimates of relative treatment effect (based on hazard ratios[HRs]) were pooled using the inverse variance method.
Source: The American Journal of Cardiology - December 20, 2021 Category: Cardiology Authors: Mamas A. Mamas, Sarah Batson, Kevin G. Pollock, Sarah Grundy, Andrew Matthew, Chris Chapman, Joana Assis Manuel, Usman Farooqui, Stephen A. Mitchell Source Type: research
Impact of Hospital Volume on Utilization and Outcomes of Sentinel Cerebral Protection System During Transcatheter Aortic Valve Implantation
Stroke remains a serious complication of transcatheter aortic valve implantation (TAVI) with a significant impact on long-term morbidity and mortality. Although the etiology of strokes is multifactorial, most are a result of embolization of debris during the procedure.1 Multiple devices have emerged aiming to reduce the incidence of stroke through cerebral embolic protection. The Sentinel cerebral protection system (CPS) is the only Food and Drug Administration-approved device in the United States.
Source: The American Journal of Cardiology - July 13, 2022 Category: Cardiology Authors: Agam Bansal, Toshiaki Isogai, Mohamed M. Gad, Grant W. Reed, Rishi Puri, Amar Krishnaswamy, Samir R. Kapadia Source Type: research
Clinical Validation of a Continuous Monitoring Mobile Cardiac Detection Device for Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide, with stroke being among the most prevalent and harmful outcomes.1 Because nearly 25% of patients with AF appear asymptomatic, questions regarding the screening of patients at risk for AF (e.g., based on CHA2DS2-VASc score) could help clinical decisions to prescribe prophylactic anticoagulation therapy for effective stroke prevention.2,3 Current evidence highlights new approaches of real-time continuous assessment of rhythmic states of AF, non-AF, and paroxysmal AF (PAF).
Source: The American Journal of Cardiology - December 9, 2022 Category: Cardiology Authors: Subhash Banerjee, Tony Das, Jerrold Grodin, Nicole Minniefield, Shirling Tsai, Rahul Banerjee, Ken Persen, Scott Novak Source Type: research
Meta-Analysis of Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement
Transcatheter aortic valve replacement (TAVR) has emerged as an effective therapy for patients with severe aortic stenosis, irrespective of surgical risks.1 Stroke due to cerebral embolization of debris is a devastating periprocedural complication of TAVR and is associated with poor outcomes. The risk of stroke could be decreased by capturing the debris using cerebral embolic protection (CEP) devices.2 An analysis of the TVT (Transcatheter Valve Therapy) Registry showed that CEPs were used in 28% of centers and 13% of all procedures.
Source: The American Journal of Cardiology - February 27, 2023 Category: Cardiology Authors: Ahmad Al-Abdouh, Mohammed Mhanna, Ahmad Jabri, Taha Ahmed, Ahmed M. Altibi, Fares Ghanem, Laith Alhuneafat, Ayman Albadawi, Mahmoud Barbarawi, Nakeya Dewaswala, Huzefa Bhopalwala, Amartya Kundu, Islam Y. Elgendy Source Type: research
Association of Frailty Status on the Causes and Outcomes of Patients Admitted With Cardiovascular Disease
Data are limited about the contemporary association between frailty and the causes and outcomes of patients admitted with cardiovascular diseases (CVD). Using the US National Inpatient Sample, CVD admissions of interest (acute myocardial infarction, ischemic stroke, atrial fibrillation (AF), heart failure, pulmonary embolism, cardiac arrest, and hemorrhagic stroke) were stratified by Hospital Frailty Risk Score (HFRS). Logistic regression was used to determine adjusted odds ratios (aORs) and 95% confidence intervals (CIs) of in-hospital mortality among different groups with frailty.
Source: The American Journal of Cardiology - January 24, 2023 Category: Cardiology Authors: Balamrit Singh Sokhal, Andrija Mateti ć, Muhammad Rashid, Jo Protheroe, Richard Partington, Christian Mallen, Mamas A. Mamas Source Type: research
Left Atrial Appendage Occlusion Devices: Are We Isolating the Right Population?
Atrial fibrillation (AF) affects more than 37 million persons worldwide contributing to significant morbidity and mortality.1 Stroke prevention with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants remains the mainstay of therapy in patients with AF because of the reduction of all-cause mortality in randomized clinical trials when compared with placebo. VKAs are necessary for those patients with valvular AF but carry a higher risk of stroke, intracranial hemorrhage, and mortality when compared with non-VKA oral anticoagulants.
Source: The American Journal of Cardiology - June 27, 2023 Category: Cardiology Authors: Navid Nafissi, Anita M. Kelsey Source Type: research
Quest for the Perfect Anticoagulant
The current referenced meta-analysis study by Selvaraj et al1 examines the relative merits of anticoagulation with a direct oral anticoagulant (DOAC) versus vitamin K antagonist (VKA) after transcatheter aortic valve implantation (TAVI) in patients meeting the indications for anticoagulation because of atrial fibrillation (AF). Although guidelines vary, the general consensus appears to indicate noninferiority to superiority of DOACs in the treatment of nonvalvular AF. In the landmark Apixiban for Reduction In Stroke and Other Thromboemoblic Events in Atrial Fibrillation trial comparing apixaban to warfarin in patients with...
Source: The American Journal of Cardiology - July 27, 2023 Category: Cardiology Authors: Bryant Fisher, Danny Chu Source Type: research
Trends in the Longitudinal Utilization of Oral Anticoagulants Among Newly Diagnosed Atrial Fibrillation Patients With Commercial, Medicare, and Medicaid Insurance
Long-term oral anticoagulation (OAC) is recommended for stroke prevention for most patients with atrial fibrillation (AF) and elevated stroke risk.1 While trends in initiation of OAC have been described,2,3 long-term trends in utilization of OAC in patients continuously followed for AF have not been adequately explored. Some healthcare systems adapted anticoagulation services to respond to disruptions during the COVID-19 pandemic.4 We thus investigated how OACs were utilized in patients with newly diagnosed AF from 2018 to 2021 across 3 insurance types: Medicare, Medicaid, and commercial.
Source: The American Journal of Cardiology - July 28, 2023 Category: Cardiology Authors: Jun Soo Lee, Sola Han, Nicole L. Therrien, Chanhyun Park, Feijun Luo, Utibe R. Essien Tags: Brief report Source Type: research
Meta-Analysis of the Outcomes of Peri-Device Leak After Left Atrial Appendage Closure
Left atrial appendage closure (LAAC) reduces the risk of thromboembolic stroke in atrial fibrillation. Peri-device leak (PDL) after LAAC may affect the subsequent risk of thromboembolism. We conducted a systematic review and meta-analysis to evaluate the effect of PDL after LAAC. We searched PubMed/Medline, Embase, and Google Scholar for studies reporting outcomes of PDL after LAAC from inception through October 2022. The primary outcome was the composite of stroke, transient ischemic attack (TIA), or systemic embolism (SE).
Source: The American Journal of Cardiology - August 10, 2023 Category: Cardiology Authors: Mostafa Reda Mostafa, Mohamed Magdi Eid, Mohamed Abuelazm, Ahmad Al-Abdouh, Mostafa Najim, Abdul Rhman Hassan, Amro A. El-Sakka, Sarath Lal Mannumbeth Renjithal, Muhammad Ahmed Malik, Sarah Mohamed, Mallory Balmer-Swain, Timir K. Paul, Andrew M. Goldsweig Source Type: research
Prehospitalization Antiplatelet Therapy and Outcomes After Saphenous Vein Graft Intervention
In conclusion, prehospital use of antiplatelet therapy was associated with a lower occurrence of major adverse cardiac events after SVG intervention. We did not find that DAPT improved outcomes compared to single antiplatelet therapy.
Source: The American Journal of Cardiology - October 26, 2012 Category: Cardiology Authors: Ralf E. Harskamp, Marcel A. Beijk, Peter Damman, Jan G. Tijssen, Renato D. Lopes, Robbert J. de Winter Tags: Coronary Artery Disease Source Type: research
Effect of Body Mass Index on Short- and Long-Term Outcomes After Transcatheter Aortic Valve Implantation
Better outcomes have been reported after percutaneous cardiac intervention in obese patients (“obesity paradox”). However, limited information is available on the effect of the body mass index on the outcomes after transcatheter aortic valve implantation (TAVI). We, therefore, sought to determine the effect of the body mass index on the short- and long-term outcomes in patients who underwent TAVI. The population consisted of 940 patients, of whom 25 (2.7%) were underweight, 384 had a (40.9%) normal weight, 372 (39.6%) were overweight, and 159 (16.9%) were obese. Overall, the obese patients were younger (79.7 ± 6.4 yea...
Source: The American Journal of Cardiology - October 26, 2012 Category: Cardiology Authors: Robert M.A. van der Boon, Alaide Chieffo, Nicolas Dumonteil, Didier Tchetche, Nicolas M. Van Mieghem, Gill L. Buchanan, Olivier Vahdat, Bertrand Marcheix, Patrick W. Serruys, Jean Fajadet, Antonio Colombo, Didier Carrié, Ron T. van Domburg, Peter P.T. de Tags: Valvular Heart Disease Source Type: research
Contribution of Three-Dimensional Transesophageal Echocardiography to Diagnosis and Management of Thrombosis of a St. Jude Mechanical Prosthesis in the Aortic Valve Position
Prosthetic valve thrombosis (PVT) is a serious complication after cardiac valve replacement and usually requires urgent management with either thrombolysis or surgery. A 38-year-old woman with history of ischemic stroke and multiple valvular surgeries including aortic St. Jude mechanical valve replacement (St. Jude Medical, St. Paul, Minnesota) presented with new-onset dyspnea on exertion. Transthoracic echocardiography and 2-dimensional transesophageal echocardiography (TEE) suggested an abnormally high gradient across the aortic valve () but could not determine the cause of the stenosis (, ). Three-dimensional (3D) TEE...
Source: The American Journal of Cardiology - January 4, 2013 Category: Cardiology Authors: Kan Liu Tags: Readers' Comments Source Type: research
